Comparative Pharmacology
Head-to-head clinical analysis: FEMSTAT versus MONISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMSTAT versus MONISTAT.
FEMSTAT vs MONISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FEMSTAT (butoconazole) is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
Butoconazole nitrate 2% vaginal cream: one applicatorful (approximately 5 g) intravaginally at bedtime for 3 days. Alternatively, butoconazole nitrate 2% single-dose vaginal cream: one applicatorful (approximately 5 g) intravaginally as a single dose.
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
None Documented
None Documented
Terminal half-life: 6-9 hours; clinical context: supports twice-daily dosing for consistent therapeutic levels.
Approximately 90-120 minutes; supports twice-daily local dosing.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites.
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Category C
Category C
Antifungal
Antifungal